<DOC>
	<DOCNO>NCT03095547</DOCNO>
	<brief_summary>Study interaction F901318 multiple dos posaconazole pantoprazole single dos cyclosporine A tacrolimus healthy subject . Pharmacokinetic profile , safety tolerability assess .</brief_summary>
	<brief_title>Drug/Drug Interactions With F901318</brief_title>
	<detailed_description>Open label randomise parallel group evaluation three four dose schedule period 21 day . Subjects randomise group follow : 1 . Cohort A : Pre-treat tacrolimus 2 mg day -9 cyclosporine A 100 mg Day -3 obtain PK curve compound prior dose F901318 . Then , F901318 360 mg b.i.d . 1 two day ( section 3.5 ) follow 240 mg b.i.d . 18 19 day ( Days 2 3-20 ) 240 mg o.m . Day 21 ( n=12 , ideally 6 female minimum 3 female , 6 male , maximum 9 male ) . Dose tacrolimus Day 9 cyclosporine A day 16 obtain full PK curve . 2 . Cohort B : F901318 360 mg b.i.d . 1 2 day ( section 3.5 ) follow 240 mg b.i.d . 5 6 day . On Day 8 , add posaconazole tablet 300 mg b.i.d . follow 300 mg daily 6 day ( Days 9-14 ) decrease F901318 dose 120 mg daily Day 8 onwards . On Day 15 , discontinue posaconazole continue F901318 6 day dose 120 mg daily ( Days 15 21 ) ( n=12 , ideally 6 female , 6 male ) . 3 . Cohort C : F901318 360 mg b.i.d . one two day ( section 3,5 ) day follow 240 mg b.i.d 19 day ( Day 1-20 ) 240 mg o.m . Day 21 . On Day 8 , add pantoprazole 40 mg daily 7 day . On Day 15 , discontinue pantoprazole continue F901318 240 mg b.i.d day 20 240 mg o.m . Day 21 ( n=12 , ideally 6 female , 6 male ) . 4 . Cohort D ( optional ) : F901318 21 day . Will conduct , necessary completion cohort A-C . Dose schedule determine basis result ongoing study F901318-01-06-16 cohort A study could 480 mg b.i.d three day follow 360 mg bid 17-19 day 360 o.m . Day 21 objective achieve maintain C12 1Âµg/mL throughout dose period ( n=12 , ideally 6 female , 6 male ) . The decision proceed take base QC 'd pharmacokinetic data PI representative ( ) Sponsor . Intensive PK evaluation F901318 metabolite concomitant medication occur follow : - Day 1 ( F901318 metabolite alone ) - Day 7 ( F901318 metabolite alone ) - Day 14 ( F901318 metabolite posaconazole cohort B ) - Day 21 ( F901318 metabolite ) Peak trough level F901318 OH metabolite ( posaconazole cohort B Days 8-20 ) obtain intermediate day . PK curve tacrolimus obtain Day -9 Day -3 Day 9 Day 15 ( cohort A ) PK curve cyclosporine A obtained Day -3 Day 1 ( prior dose F901318 ) Day 18 Day 21 ( cohort A ) Adverse event 12 lead ECGs record blood urine sample obtain safety evaluation throughout . All subject return post-study visit 8 10 day last dose study medication .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>1 . Subjects males female ethnic origin 18 55 year age weigh 60 100 kg inclusive . 2 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation 3 . Hepatic transaminase must within normal limit congenital non haemolytic hyperbilirubinaemia acceptable . 4 . Negative pregnancy test females child bear potential screening Day 1 5 . Subjects give write informed consent participate study abide study restriction 1 . Female male subject , whose partner use least three month prior screen willing use appropriate contraception study 3 month end dose ( Section 5.4.3 ) . 2 . Pregnancy lactation . 3 . For cohort A , clinically significant infection within past 6 month recur herpes infection within past 6 month history tuberculosis 4 . Subjects receive prescribed systemic topical medication within 14 day dose administration unless opinion Investigator medical monitor medication interfere study procedure compromise safety 5 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day dose administration ( exception vitamin/mineral supplement ) unless opinion Investigator medical monitor medication interfere study procedure compromise safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>